Autolus Therapeutics plc
AUTLNasdaq
$1.44
↓ -1.4%Jul 17 close · end-of-day
Price
1Y↓ -41.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$383.2M
Enterprise Value
$153.8M
P/E
—
P/S
4.1
P/B
3.5
EV/EBITDA
—
PEG
—
FCF Yield
-74.8%
Dividend Yield
—
Revenue (TTM)
$92.6M
Net Income (TTM)
-$289.0M
Free Cash Flow (TTM)
-$286.8M
Gross Margin
—
Operating Margin
-285.9%
Net Margin
-312.0%
ROE
-265.5%
ROIC
—
Debt / Equity
—
Net Cash
$229.4M
Return 1Y
-40.5%
Company profile
Autolus Therapeutics plc develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trials for adult ALL. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development.
- CEO
- Christian M. Itin
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 330
- Website
- autolus.com
Earnings
AUTL Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$26.2M↑ +191.9%
Diluted EPS-$0.27↑ +3.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $1.7M | $10.1M | $75.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$168.1M | -$141.1M | -$143.4M | -$179.7M | -$241.4M | -$270.5M |
| Net income | -$142.1M | -$142.1M | -$148.8M | -$208.4M | -$220.7M | -$287.5M |
| Diluted EPS | -$2.76 | -$1.97 | -$1.57 | -$1.20 | -$0.86 | -$1.08 |
| Operating cash flow | -$117.8M | -$117.9M | -$112.3M | -$145.6M | -$206.3M | -$283.6M |
| Free cash flow | -$132.4M | -$126.7M | -$123.1M | -$156.6M | -$228.3M | -$302.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | -10583.1% | -2385.6% | -358.9% |
| Net margin | — | — | — | -12272.3% | -2180.5% | -381.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $29,000.00 | $9.0M | $20.9M | $21.2M | $24.3M | $26.2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$58.9M | -$67.9M | -$75.9M | -$65.2M | -$61.2M | -$71.6M | -$72.5M | -$59.5M |
| Net income | -$58.3M | -$82.1M | -$27.6M | -$70.2M | -$47.9M | -$79.1M | -$90.3M | -$71.6M |
| Diluted EPS | -$0.22 | -$0.31 | -$0.09 | -$0.26 | -$0.18 | -$0.30 | -$0.34 | -$0.27 |
| Operating cash flow | -$51.1M | -$76.7M | -$37.9M | -$75.6M | -$72.8M | -$67.9M | -$67.3M | -$65.3M |
| Free cash flow | -$51.9M | -$86.3M | -$49.0M | -$83.8M | -$80.1M | -$72.3M | -$68.2M | -$68.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | -261600.0% | -726.3% | -292.6% | -337.9% | -298.3% | -227.0% |
| Net margin | — | — | -95193.1% | -781.1% | -229.0% | -373.3% | -371.9% | -273.1% |
Company news
Jul 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.